Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/830"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"Route of administration: oral
polymorphic enzyme: NO
study duration: 14 days diltiazem pretreatment
population: 5 male, 5 women
ages:19-35
(mean AUC_i)/(mean AUC) = 55.4/11.5
description:
A fixed-order study was conducted in 10 healthy volunteers with a 2-week washout period between the phases. In one arm of the study, a single 20-mg dose of simvastatin was administered orally; the second arm entailed administration of a single 20-mg dose of simvastatin orally after 2 weeks of treatment with 120 mg diltiazem twice a day. RESULTS: Diltiazem significantly increased the mean peak serum concentration of simvastatin by 3.6-fold (P < .05) and simvastatin acid by 3.7-fold (P < .05). Diltiazem also significantly increased the area under the serum concentration-time curve of simvastatin 5-fold (P < .05) and the elimination half-life 2.3-fold (P < .05)."
|
| dc:creator | |
| dc:date |
"05/29/2007 10:27:50"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ diltiazem_increases_auc_simvastatin, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1866 }